



## LJMU Research Online

**Petrovic, M, Maganaris, CN, Deschamps, K, Verschueren, SM, Bowling, FL, Boulton, AJ and Reeves, ND**

**Altered Achilles tendon function during walking in people with diabetic neuropathy: implications for metabolic energy saving.**

<http://researchonline.ljmu.ac.uk/8138/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Petrovic, M, Maganaris, CN, Deschamps, K, Verschueren, SM, Bowling, FL, Boulton, AJ and Reeves, ND (2018) Altered Achilles tendon function during walking in people with diabetic neuropathy: implications for metabolic energy saving. Journal of Applied Physiology (1985). ISSN 8750-7587**

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

1 Altered Achilles tendon function during walking in people with diabetic neuropathy:  
2 implications for metabolic energy saving

3

4

5

6 Petrovic M<sup>1</sup>, Maganaris CN<sup>4</sup>, Deschamps K<sup>3</sup>, Verschueren SM<sup>3</sup>, Bowling FL<sup>2</sup>, Boulton  
7 AJM<sup>2,5</sup> & Reeves ND<sup>1</sup>.

8

9 <sup>1</sup>School of Healthcare Science, Faculty of Science & Engineering, Manchester  
10 Metropolitan University, UK, <sup>2</sup>Faculty of Medical & Human Sciences, University of  
11 Manchester, UK, <sup>3</sup>Department of Rehabilitation Sciences, Katholieke Universiteit  
12 Leuven, Belgium, <sup>4</sup>School of Sport and Exercise Sciences, Liverpool John Moores  
13 University, UK, <sup>5</sup>Diabetes Research Institute, University of Miami, Miami, FL, USA

14

15

16 Running title: Elastic energy storage in diabetic neuropathy

17

18

19

20

21

22

23 Corresponding author:

24 Neil D. Reeves

25 School of Healthcare Science

26 Faculty of Science & Engineering

27 Manchester Metropolitan University

28 John Dalton Building, Oxford Road,

29 Manchester M1 5GD

30 United Kingdom

31 Tel: +44 161-247-5429

32 Email: [N.Reeves@mmu.ac.uk](mailto:N.Reeves@mmu.ac.uk)

33

34

35

36

37

38

39

40

41 **ABSTRACT**

42 The Achilles tendon (AT) has the capacity to store and release elastic energy during  
43 walking, contributing to metabolic energy savings. In diabetes patients, it is  
44 hypothesised that a stiffer Achilles tendon may reduce the capacity for energy saving  
45 through this mechanism, thereby contributing to an increased metabolic cost of walking  
46 (CoW). The aim of this study was to investigate the effects of diabetes and diabetic  
47 peripheral neuropathy (DPN) on the Achilles tendon and plantarflexor muscle-tendon  
48 unit behaviour during walking. Twenty three non-diabetic controls (Ctrl); 20 diabetic  
49 patients without peripheral neuropathy (DM) and 13 patients with moderate/severe  
50 DPN, underwent gait analysis using a motion analysis system, force plates and  
51 ultrasound measurements of the gastrocnemius muscle, using a muscle model to  
52 determine Achilles tendon and muscle-tendon length changes. During walking, the DM  
53 and particularly the DPN group displayed significantly less Achilles tendon elongation  
54 (Ctrl: 1.81; DM 1.66; DPN: 1.54 cm), higher tendon stiffness (Ctrl: 210; DM: 231; DPN:  
55 240 N/mm) and higher tendon hysteresis (Ctrl: 18; DM: 21; DPN: 24 %) compared to  
56 controls. The muscle fascicles of the gastrocnemius underwent very small length  
57 changes in all groups during walking (~0.43cm), with the smallest length changes in the  
58 DPN group. Achilles tendon forces were significantly lower in the diabetes groups  
59 compared to controls (Ctrl: 2666; DM: 2609; DPN: 2150 N). The results strongly point  
60 towards the reduced energy saving capacity of the Achilles tendon during walking in  
61 diabetes patients as an important factor contributing to the increased metabolic CoW in  
62 these patients.

63 Keywords: elastic energy storage, tendon stiffness, lower limb, biomechanics, diabetes.

64

65 **New & Noteworthy**

66 From measurements taken during walking we observed that the Achilles tendon in  
67 people with diabetes and particularly people with diabetic peripheral neuropathy was  
68 stiffer, elongated less and was subject to lower forces compared to controls without  
69 diabetes. These altered properties of the Achilles tendon in people with diabetes reduce  
70 the tendon's energy saving capacity and contribute towards the higher metabolic energy  
71 cost of walking in these patients.

72

73 **INTRODUCTION**

74 Diabetes mellitus (DM) is a very prevalent global chronic disease in older adults and is  
75 associated with a number of complications including cardiovascular disease, peripheral  
76 arterial disease, retinopathy and poor wound healing (16, 14). One of the most common  
77 complications of diabetes is diabetic peripheral neuropathy (DPN), with the incidence  
78 reported to range between 13 and 68% (44, 6). Diabetes and DPN impact negatively on  
79 gait and mobility with implications for quality of life. Diabetes and DPN cause muscle  
80 weakness and affect sensory perception altering walking strategy and causing  
81 impairments to balance control (13, 30, 20, 5).

82 The muscle-tendon complex is central to all movement tasks, with skeletal muscle  
83 generating force, which is transmitted to the skeleton via viscoelastic tendons. In  
84 addition to their force transmitting role, tendons also play an important role in energy  
85 saving during walking by storing (during stretching) and returning (upon recoil) elastic  
86 energy (37, 38, 39, 2). In particular, the Achilles tendon is a long tendon that is

87 important for storing and releasing elastic energy during walking and as such, plays an  
88 important role in metabolic energy saving, as it actually 'spares' the muscle from  
89 performing a large part of the work (3).

90 Both muscles and tendons are highly malleable tissues, which can modify their  
91 properties in response to the habitual level of physiological loading and also the  
92 metabolic environment (36, 1, 17). Animal studies show that diabetes causes non-  
93 enzymatic glycation of soft tissues, including tendons (34). This non-enzymatic glycation  
94 causes increased cross-linking, increasing the stiffness and modulus of the tendon (35,  
95 33). Stiffening of the tendon reduces the degree to which it can be stretched, affecting  
96 its potential for storing (and subsequently releasing) elastic strain energy during walking  
97 and also limiting the ankle joint range of motion (11, 19, 29). In humans, calcification  
98 and fascicle disruption have been observed in the diabetic human Achilles tendon (4).  
99 Tendons exhibit relatively low mechanical hysteresis, which is defined as the energy  
100 lost upon recoil of the tendon (27). In addition to tendon stiffness, the hysteresis of the  
101 tendon could also be affected by diabetes. Hysteresis has been shown to increase in  
102 humans with ageing (37). An increase in hysteresis would also reduce metabolic energy  
103 saving by the Achilles tendon during walking.

104 In dynamometry tests, Couppé et al. (10) found Achilles tendon stiffness and skin  
105 connective tissue cross-linking were greater in diabetes patients compared with  
106 controls. Cronin et al. (11) found that Achilles tendon length changes during walking at  
107 self-selected speed were attenuated in diabetes patients and that this was inversely  
108 correlated with diabetes duration.

109 The impact of changes in Achilles tendon and plantarflexor muscle function induced by  
110 diabetes and diabetic neuropathy remain unknown during walking. The aim of this study  
111 was to investigate the effects of diabetes and diabetic peripheral neuropathy on plantar  
112 flexor muscle-tendon behaviour during walking at self-selected and controlled speeds.  
113 We hypothesized that the Achilles tendon would function in a manner that reduced its  
114 energy contribution during walking in diabetes patients and particularly in those with  
115 diabetic neuropathy compared to controls. As a result, a greater contribution would be  
116 required from the plantarflexor muscles for walking, requiring more energy and  
117 contributing to the higher cost of walking (CoW) that we have recently reported in  
118 people with diabetes (32).

119

## 120 **MATERIALS AND METHODS**

### 121 **Participants**

122 Fifty-six participants were involved in this study. Participants were allocated into one of  
123 three groups based upon defined criteria: patients with diabetes and moderate-severe  
124 peripheral neuropathy (DPN, n=13), patients with diabetes but no neuropathy (DM,  
125 n=20) and healthy controls without diabetes or peripheral neuropathy (Ctrl, n=23). Major  
126 exclusion criteria included: disorders of the vestibular system, severe vascular disease,  
127 neurological, rheumatic disease, cerebral injury, unstable ischemic heart,  
128 musculoskeletal injury, foot or lower limb amputation (amputation of the hallux;  
129 amputation of more than two lesser toes on one foot; amputation of part of/whole foot)  
130 and open foot ulcer and recent surgery affecting gait. Participant characteristics are  
131 displayed in Table 1.

## 132 **Diagnosis of Diabetic Peripheral Neuropathy**

133 The presence and severity of peripheral neuropathy was assessed by using the  
134 modified Neuropathy Disability Score (mNDS) and the vibration perception threshold  
135 (VPT). The mNDS is a composite score taken from tests measuring the participant's  
136 ability to discriminate temperature, detect pain, vibration and the Achilles tendon reflex  
137 (6). The VPT is an assessment performed using the probe of a neurothesiometer on the  
138 apex of the hallux and increasing the level of vibration until detected by the participant.  
139 A random blood glucose test was performed in the Ctrl group to confirm the absence of  
140 diabetes (<7 mmol/l) and the above neuropathy tests were conducted to confirm the  
141 absence of neuropathy in the Ctrl group resulting from any aetiology.

142

## 143 **Gait analysis**

144 Gait analysis was performed for the purpose of assessing the contribution of the  
145 plantarflexor muscle-tendon complex and the capacity for elastic energy storage and  
146 release via the Achilles tendon. To investigate whether the changes are dependent on  
147 the walking speed we asked participants to walk along a 10-metre walkway in the gait  
148 laboratory at their self-selected speed, as well as at a standardized speed of 1.0 m/s.  
149 Walking at the standardized speed was controlled by measuring the velocity of a marker  
150 attached to the sacrum after each trial from the motion analysis data and providing  
151 immediate feedback for participants as to whether they needed to walk more quickly or  
152 more slowly on the next trial to achieve the required speed (1.0 m/s). Kinematic data  
153 were collected at 100 Hz using a 10-camera Vicon motion capture system (Vicon,  
154 Oxford, UK) and a full-body modified Plug-In-Gait marker set consisting of 54 markers.

155 Where possible motion analysis markers were placed directly onto the skin; to minimise  
156 movement artefacts resulting from loose clothing, all participants wore tight-fitting shorts  
157 and t-shirts. Ground reaction forces were measured at 1000 Hz from three force  
158 platforms (Kistler, Zurich, Switzerland) embedded into the walkway and synchronised  
159 with the kinematic data. We have used standard procedures and systems for the  
160 calculation of joint moments that are used routinely and have been widely accepted by  
161 the biomechanics community (43, 9). Walking trials were repeated until three 'clean' foot  
162 contacts with the force platforms were made with right limb, for both speed conditions.  
163 During walking, an ultrasonographic imaging device (Aloka SSD-5000, Tokyo, Japan)  
164 operating at 25 Hz was used to measure gastrocnemius medialis (MG) muscle fascicle  
165 length changes *in vivo*. For these measurements, a linear 7.5 MHz probe with 60 mm  
166 field of view was secured around the right lower leg in the mid-sagittal plane of the MG  
167 muscle with a custom-built fixation device (Fig. 1). The ultrasound scanning was  
168 synchronized with recordings of the kinematic and kinetic data. We have previously  
169 shown a high reliability for this technique in measuring fascicle lengths, with an intra-  
170 class correlation coefficient of 0.8 (42). All participants wore specialist diabetic shoes  
171 (MedSurg, Darco, Raisting, Germany) with a neutral foot-bed, ensuring the diabetic  
172 patients walked with safe, appropriate footwear whilst controlling for the effects of  
173 footwear on the measured variables by standardising across all groups (Fig. 1).

174

#### 175 **Dynamometry measurements: Measurement of Maximal Plantarflexion Strength**

176 Isometric plantarflexor maximal voluntary contraction (MVC) joint moment (maximum  
177 strength) was recorded with participants laying prone with the knee in full extension.



178 The axis of rotation of the ankle, defined as the line connecting the two malleoli, was  
179 carefully aligned with the axis of rotation of the dynamometer and the right foot secured  
180 to the foot adapter of an isokinetic dynamometer (Cybex NORM, Cybex International,  
181 New York, NY, USA). Straps were used around the ankle and also the hips to prevent  
182 extraneous movements during maximal plantarflexions. Prior to testing subjects became  
183 familiarised with the procedures involved. Participants were instructed to perform  
184 maximal isometric plantarflexion contractions at joint angles of 0, 5 and 10 degrees of  
185 dorsiflexion, where zero degrees was neutral ankle position: the footplate of the  
186 dynamometer perpendicular to the longitudinal axis of the tibia. The subjects were  
187 verbally encouraged to produce their maximum effort. Contractions were performed in a  
188 randomized order. Two contractions were performed at each ankle angle by allowing a  
189 1-min rest interval between bouts and the highest value was considered as the MVC at  
190 each ankle angle. Results were subsequently normalised to body mass.

191

## 192 **Data processing**

193 The purpose of the data analysis was to quantify the Achilles tendon and plantarflexor  
194 muscle-tendon complex characteristics during walking. The MG muscle was assessed  
195 as representative of the plantarflexor muscle group (41, 44) and measured from every  
196 frame of the ultrasound recordings throughout the entire stance phase. On each  
197 ultrasound frame, three lines were defined automatically using a custom-script written in  
198 MATLAB software (12): one line tracked the superficial aponeurosis, a second line was  
199 matched with the deep aponeurosis, and a third line defined the fascicular path of the  
200 fascicle movement. From these three lines, fascicle length and pennation angle were

201 calculated on each frame of ultrasound data. Muscle fascicle length was defined as the  
202 distance between the superficial and deep aponeurosis parallel to the lines of  
203 collagenous tissue. Pennation angle ( $\alpha$ ) was defined as the angle between the  
204 collagenous tissue and the deep aponeurosis, since this deep pennation angle is the  
205 one through which force is transmitted along the tendon. The equations by ~~Menegalde~~  
206 ~~et al.~~ Grieve et al. (10) were used to calculate the MG muscle-tendon complex (MTC)  
207 length change (muscle plus free tendon and aponeurosis in both distal and proximal  
208 ends) using the fascicle length changes and the ankle and knee joint displacements  
209 measured during walking over the stance phase. The length of the tendon (including  
210 both the free tendon and aponeurosis) was found by subtracting muscle fascicle length  
211 projected in the direction of the line of force application from the muscle-tendon  
212 complex (MTC) length for each time instant. Thus:

$$213 \quad l^t = l^{MTC} - l^m \cos \alpha$$

214  
215 where  $l^t$  is the length of the tendon,  $l^{MTC}$  is the length of the MTC,  $l^m$  is the  
216 ultrasound-measured muscle fascicle length, and  $\alpha$  is the ultrasound-measured  
217 pennation angle.

218 Real-time ultrasound scanning was used to determine MG muscle fascicle length  
219 changes, while musculotendon complex (MTC) length changes were estimated from  
220 ankle and knee joint kinematics. Muscle fascicle and tendon properties were assumed  
221 to be consistent along the length of the MTC. The muscle fascicles were also assumed  
222 to be parallel to one another. The validity and reliability of the ultrasound measurements  
223 *in vivo* during walking have been critically assessed in other studies on the same and  
224 similar populations, reporting ICC values between 0.78 and 0.94 (21, 28, 31, 41).

## 225 **Achilles tendon force calculation and magnetic resonance imaging scanning**

226 Achilles tendon forces were calculated during walking throughout the stance phase by  
227 dividing the net plantarflexion joint moments (Nm) by the Achilles tendon internal  
228 moment arm length measured using a 0.25T magnetic resonance imaging (MRI)  
229 scanner (E-Scan, Esaote Biomedica, Genoa, Italy). The MRI scanning was performed  
230 with the participant in the upright standing position (i.e., full weight-bearing MRI) to  
231 mimic as closely as possible the conditions experienced on the ankle joint and Achilles  
232 tendon during walking. To calculate the Achilles tendon moment arm we used the  
233 Reauleaux method for identification of the ankle joint centre of a rotation, with the  
234 principle of a segment (the talus) rotating about a stationary (tibia) segment (40, 26).  
235 The centre of rotation was first defined using MRI images taken at 10 degrees of  
236 plantarflexion and 10 degrees of dorsiflexion, after which the distance between the  
237 Achilles tendon action line and the centre of rotation was measured on an MRI scan  
238 performed at the neutral ankle position.

239 The plantarflexion joint moments were derived from the kinematic and kinetic data using  
240 Visual 3D software (C-motion Inc., MD, USA). Elongation of the Achilles tendon was  
241 calculated as described in the above section. The Achilles tendon force and elongation  
242 were normalised to 100 points to represent the entire stance phase. Therefore, the  
243 Achilles tendon force-elongation curve was derived, as shown in Fig. 5, where the  
244 loading phase (arrow pointing up) represents 10-70% of the stance phase and the  
245 unloading phase (arrow pointing down) the final 30%, as described in Table 2.

246

## 247 **Stiffness and hysteresis during walking**

248 The Achilles tendon stiffness was calculated from the measurements taken during  
249 walking as the slope of the loading force-elongation curve by dividing the estimated  
250 tendon force (N) by the tendon's elongation (mm) over a force region between 500 and  
251 1,500 N. This force region (500-1,500 N) was selected because it allowed comparison  
252 between groups over a common force region and enabled the use of measured data  
253 points on the force-elongation curve without the need to extrapolate. Mechanical  
254 hysteresis is a measure of the energy dissipated upon tendon recoil and converted to  
255 heat, an important feature of the mechanical properties of tendon. Mechanical  
256 hysteresis was defined as the area between the loading ( $L$ ) and unloading ( $UnL$ ) curves  
257 and expressed as a percentage:

$$258 \qquad \text{Mechanical hysteresis} = (L - UnL) / L \cdot 100$$

259

## 260 **Statistics**

261 A one-way analysis of variance (ANOVA) was performed for all variables to assess  
262 between group differences (Ctrl; DM; DPN). If the ANOVA was significant, a Fisher's  
263 least significant difference (LSD) post-hoc test was used to test for differences between  
264 the diabetes groups (DM and DPN) and the control group. All values presented are  
265 means and standard deviation. Significance was accepted at  $p < 0.05$ .

266

## 267 **RESULTS**

268

### 269 **Participant characteristics**

270 Participant characteristics are shown in Table 1. There were no significant differences  
271 between the groups in age and BMI (Table 1).

272

### 273 **Peripheral neuropathy assessments**

274 As expected, the DPN group displayed significantly higher values for the VPT and the  
275 mNDS compared to the Ctrl group (Table 1). The VPT and mNDS for the DM group  
276 were not significantly different from the Ctrl, underlining that this diabetes patient group  
277 had no neuropathy (Table 1).

278

### 279 **Lower limb kinetics and kinematics during walking**

280 Peak ankle plantarflexion joint moments were significantly lower ( $P<0.01$ ) in the DPN  
281 and the DM compared to the Ctrl group for both self-selected and 1.0 m/s walking  
282 speeds (Table 2). A significantly ( $P<0.01$ ) lower ankle and knee joint range of motion  
283 (RoM) was observed in the DPN and the DM groups compared to the Ctrl group for self-  
284 selected and 1.0 m/s walking speeds (Table 2).

285

### 286 **Plantarflexor muscle-tendon unit behaviour during walking**

287 There were significant differences in the tendon length change between the groups at  
288 self-selected walking speed (Ctrl: 1.81 cm; DM 1.66 cm; DPN: 1.54 cm;  $P<0.01$ ) as well  
289 as 1.0 m/s (Ctrl: 1.67 cm; DM 1.51 cm; DPN: 1.47 cm;  $P<0.01$ ), where the DPN group  
290 expressed smaller tendon length changes. During walking, the DM and particularly the  
291 DPN groups displayed significantly higher tendon stiffness (Ctrl: 210; DM: 231; DPN:  
292 240 N/mm:  $P<0.01$ ) and higher tendon hysteresis (Ctrl: 18; DM: 21; DPN: 24%:  $P<0.01$ )

293 compared to controls. There were no differences in the fascicle lengths during standing  
294 between the groups ( $P>0.05$ ). Average fascicle length change data during the stance  
295 phase show that the DPN group was significantly lower ( $P<0.01$ ) than the Ctrl group for  
296 both self-selected speed and 1.0 m/s during two different phases, 10-70% and 70-100%  
297 of the stance (Table 2), while the DM group was different from the Ctrl group only at 1.0  
298 m/s (Table 2). Significant differences in the MTC length change were found between the  
299 DPN and the Ctrl as well as the DM and the Ctrl groups for both walking speeds (Table  
300 2). Significant differences in the pennation angle changes were found between DPN  
301 and the Ctrl as well as the DM and the Ctrl groups for both speeds during loading and  
302 unloading phases (Table 2).

303

## 304 **DISCUSSION**

305 This study has shown for the first time that there is reduced Achilles tendon elongation  
306 during the loading phase of walking (10-70% stance) and reduced tendon recoil during  
307 the subsequent propulsive phase (70-100% stance) in people with diabetes and to the  
308 greatest extent in those with DPN compared to controls (Table 2; Fig. 3). Further  
309 novelty is in uncovering the mechanism of this during walking, by showing that people  
310 with diabetes and particularly those with DPN demonstrated a higher stiffness and  
311 hysteresis of the Achilles tendon compared to the Ctrl group (Fig. 4; Table 5). Taken  
312 together the present findings strongly indicate a reduced elastic energy contribution  
313 from the Achilles tendon during walking in people with diabetes and to a greater extent  
314 in those with DPN, with implications for increasing the metabolic CoW in patients with  
315 diabetes and DPN as we have recently shown (32).

316 The increased tendon stiffness observed in the diabetes groups shows that for the  
317 same application of force, the Achilles tendon is less extensible during walking, which  
318 means that less energy can be stored. The increased stiffness is further compounded  
319 by the fact that less force is applied on the Achilles tendon in the DM and particularly  
320 the DPN groups (Fig 5; Table 2). The lower tendon forces applied during walking in  
321 diabetic patients is the result of lower joint moments being developed, which reflect a  
322 natural strategy to lower the demands of walking (7, 8, 22). This requirement to lower  
323 the demands of walking stems from the lower muscular capabilities of diabetes patients,  
324 exemplified by the lower maximum plantarflexor strength observed in both diabetes  
325 groups of the present study (Fig. 6). The maximum plantarflexor strength deficits were  
326 most marked as the ankle moved further into dorsiflexion (Fig. 6), which is closely

327 aligned with the position of the ankle during walking when the Achilles tendon is  
328 undergoing elongation (Fig. 3 & 4). Hence, lower moments developed while the ankle is  
329 in dorsiflexion during walking means lower forces applied to elongate and store energy  
330 within the Achilles tendon.

331 Once energy is stored in the Achilles tendon, the majority is returned upon tendon  
332 recoil, but some is lost due to internal damping, known as hysteresis. It was found that  
333 Achilles tendon hysteresis was significantly higher in people with diabetes, and to the  
334 greatest extent in those with DPN compared to controls. This further compounds the  
335 effect of reduced energy stored in the tendon upon loading resulting from increased  
336 tendon stiffness, since a lower proportion of the energy stored will be returned upon  
337 recoil.

338 The results indicate that the MTC length changes during walking are dependent upon  
339 the changes in ankle and knee joint angles (Fig. 3 & 4). Although the magnitude of the  
340 between-group differences were relatively small (~2 deg at the ankle and ~4 deg at the  
341 knee), a significantly smaller ankle and knee joint range of motion during walking was  
342 found in the DPN group compared to the controls (Fig. 4). This resulted in significantly  
343 smaller MTC length changes during walking in the diabetes and particularly in the DPN  
344 group compared to controls (Fig. 3; Table 1). The present findings of reduced tendon  
345 elongations are in line with previous work by Cronin et al. (11) showing that the Achilles  
346 tendon length changes during walking are attenuated in long-term diabetic patients, but  
347 without reference to a diabetic peripheral neuropathy group.

348 During walking the muscle fascicles of the gastrocnemius underwent very little length  
349 change compared to the Achilles tendon and the MTC (Fig. 3) and they could be



350 considered as acting near-isometrically. Indeed, near-isometric behaviour of  
351 plantarflexor muscle fascicles has been previously reported in healthy young  
352 populations Fukunaga (18), Lichtwark (25), Ishikawa (23), Roberts (39), which functions  
353 to allow the Achilles tendon to absorb the length changes of the MTC, thereby  
354 facilitating elastic energy storage within the tendon. Although the muscle fascicles were  
355 found to actually shorten very little during the propulsive phase of gait in any group (Fig.  
356 3), the reduced elastic energy contribution from the Achilles during walking in people  
357 with diabetes and particularly in those with DPN indicates that the plantarflexor muscles  
358 would need to contribute a greater proportion of the work, thereby increasing the  
359 metabolic CoW. Although we did not find a greater length change of the gastrocnemius  
360 muscle fascicles for the diabetes groups in the present study, it could be speculated that  
361 the uni-articular soleus muscle undergoes greater shortening in the diabetes groups,  
362 contributing to the higher muscular contribution and increased CoW. Despite the near-  
363 isometric behaviour of muscle fascicles during walking, pennation angles underwent  
364 changes in the region of between 22-32 deg, reflecting elongation of the Achilles tendon  
365 and aponeurosis, with smaller pennation angle changes seen in the DPN group (Table  
366 2).

367 The tendon stiffness data measured during walking in the present study are comparable  
368 with a number of previous *in vivo* human studies of the Achilles tendon measured using  
369 a dynamometry approach and reporting values ranging between 149 and 207 N/mm  
370 (31, 21, 25, 28). The increased tendon stiffness likely results from increased collagen  
371 cross-linking due to diabetes and DPN (33, 34), but a thicker tendon with a larger cross-  
372 sectional area may also play a role if present (21). Also, values for tendon hysteresis

373 from the present study measured during walking are comparable to dynamometry-  
374 based methods reported previously in the literature for the Achilles tendon in the range  
375 between 5 and 26 % (31, 25, 28, 15, 24). It should be noted, that whilst previous studies  
376 have derived tendon stiffness and hysteresis values from static dynamometry  
377 measurements, the present study is unique in determining these tendon properties  
378 during walking. It should be acknowledged as a limitation, however, that tendon length  
379 changes can result from both tendon loading and also joint rotations. Therefore,  
380 measurements of tendon elongation in the previous and present studies reflect not only  
381 'true' elongations resulting from tensile forces, but also elongation due to joint rotations.  
382 Whilst this is more easily 'corrected' for with the dynamometry-based approach, the  
383 complexity of the unique approach followed in the present study mean that joint  
384 rotations are more challenging to account for. Nevertheless, the magnitudes of  
385 between-group differences in joint rotations were relatively small and therefore unlikely  
386 to impact on the present findings (Fig. 4; Table 1).

387 We calculated ankle joint moments using the inverse dynamics technique, which  
388 provides the net joint moment. In calculating the net joint moment, this technique takes  
389 into account agonist and antagonistic moments acting around the joint, but cannot  
390 distinguish differences in for example, the level of antagonist muscle coactivation  
391 between groups. Using this standard approach to calculate Achilles tendon forces, an  
392 assumption is made that that the force generated by all of the plantarflexor muscles acts  
393 through the Achilles tendon. Based on data of muscle physiological cross-sectional area  
394 (17), the soleus and gastrocnemius muscles will contribute 83% of the plantarflexion

395 force, but it should be acknowledged that there are other smaller plantarflexor muscles  
396 contributing the remaining 17% of the force that do not act through the Achilles tendon.  
397 The present study has shown reduced Achilles tendon elongation, increased stiffness  
398 and hysteresis during walking in people with diabetes and particularly those with DPN,  
399 compared to controls. The implications of these findings are a reduced storage and  
400 release of elastic energy from the Achilles tendon of diabetes and DPN patients during  
401 walking, presumably requiring a greater contribution to the work from plantarflexor  
402 muscles. The results strongly point towards the reduced energy saving capacity of the  
403 Achilles tendon in diabetes and DPN patients as an important factor contributing to the  
404 increased metabolic CoW in these patients.

405

#### 406 **ACKNOWLEDGMENTS**

407 The authors would like to thank to Help DiaBEATes Network (“Research for the  
408 Future”), for assistance with participant recruitment and the staff of the Manchester  
409 Diabetes Centre.

410

#### 411 **GRANT**

412 This study was funded by the European Commission through MOVE-AGE, an Erasmus  
413 Mundus Joint Doctorate programme.

414

#### 415 **COMPETING INTERESTS**

416 None of the authors had any financial or personal conflict of interest with regard to this  
417 study.

418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456

## REFERENCES

1. **Abate M, Schiavone C, Di Carlo L, Salini V.** Achilles tendon and plantar fascia in recently diagnosed type II diabetes: role of body mass index. *Clin Rheumatol* 31: 1109–1113, 2012.
2. **Alexander RM.** Tendon elasticity and muscle function. *Comp Biochem Physiol A Mol Integr Physiol* 133: 1001–1011, 2002.
3. **Alexander RM, Bennet-Clark HC.** Storage of elastic strain energy in muscle and other tissues. *Nature* 265: 114-7, 1977.
4. **Batista F, Nery C, Pinzur M, Monteiro AC, de Souza EF, Felipe FH, Alcantara MC, Campos RS.** Achilles tendinopathy in diabetes mellitus. *Foot Ankle Int* 29: 498–501, 2008.
5. **Bonnet C, Carello C, Turvey MT.** Diabetes and postural stability: review and hypotheses. *J Mot Behav*: 41: 172–190, 2009.
6. **Boulton AJM.** Management of Diabetic Peripheral Neuropathy. *Clin Diab* 23: 9–15, 2005.
7. **Brown SJ, Handsaker JC, Bowling FL, Maganaris CN, Boulton AJM, Reeves ND.** Do patients with diabetic neuropathy use a higher proportion of their maximum strength when walking? *J Biomech* 47: 3639–3644, 2014.
8. **Brown SJ, Handsaker JC, Maganaris CN, Bowling FL, Boulton AJM, Reeves ND.** Altered joint moment strategy during stair walking in diabetes patients with and without peripheral neuropathy. *Gait Posture* 46: 188–193, 2016.
9. **Camomilla V, Cereatti A, Giovanni Cutti A, Fantozzi S, Stagni R, Vannozzi G.** Methodological Factors Affecting Joint Moments Estimation in Clinical Gait Analysis: A Systematic Review. *Biomed Eng Online* 16: 106, 2017.


- 457 10. **Couppé C, Svensson RB, Kongsgaard M, Kovanen V, Grosset JF,**  
458 **Snorgaard O, Magnusson SP.** Human Achilles tendon glycation and function in  
459 diabetes. *J Appl Physiol* 120: 130–137, 2016.  
460
- 461 11. **Cronin NJ, Peltonen J, Ishikawa M, Komi PV, Avela J, Sinkjaer T, Voigt M.**  
462 Achilles tendon length changes during walking in long-term diabetic patients. *Clin*  
463 *Biomech* 25: 476–482, 2010.  
464
- 465 12. **Cunningham R.** The application of b-mode ultrasonography for analysis of  
466 human skeletal muscle, PhD thesis, 2015, <https://e-space.mmu.ac.uk/582279/>.  
467
- 468 13. **Dingwell JB, Cavanagh PR.** Increased variability of continuous overground  
469 walking in neuropathic patients is only indirectly related to sensory loss. *Gait*  
470 *Posture* 14: 1–10, 2001.  
471
- 472 14. **Fletcher GF, Balady GJ, Amsterdam E, Chaitman B, Eckel R, Fleg J, Rodney**  
473 **R.** AHA Scientific Statement. *Circulation* 6083: 1694–1740, 2001.  
474
- 475 15. **Fletcher JR, Groves EM, Pfister TR, MacIntosh BR.** Can muscle shortening  
476 alone, explain the energy cost of muscle contraction in vivo? *Eur J Appl Physiol*  
477 11: 2313–2322, 2013.  
478
- 479 16. **Fowler MJ.** Micro-vascular and macro-vascular complications of diabetes. *Clin*  
480 *diabetes* 26: 77-82, 2008.  
481
- 482 17. **Fukunaga T, Kawakami Y, Fukashiro S, Kanehisa H, Maganaris CN.** In vivo  
483 behaviour of human muscle tendon during walking. Proceedings. *Biological*  
484 *Sciences / The Royal Society* 268: 229–233, 2001.  
485
- 486 18. **Fukunaga, T., Miyatani, M., Tachi, M., Kouzaki, M., Kawakami, Y., Kanehisa,**  
487 **H.** Muscle volume is a major determinant of joint torque in humans. *Acta*  
488 *Physiologica Scandinavica* 172, 249–255, 2001.  
489
- 490 19. **Giacomozzi C, D’Ambrogi E, Uccioli L, MacEllari V.** Does the thickening of  
491 Achilles tendon and plantar fascia contribute to the alteration of diabetic foot  
492 loading? *Clinical Biomechanics* 20: 532–539, 2005.  
493
- 494 20. **Goldberg A, Russell JW, Alexander NB.** Standing balance and trunk position  
495 sense in impaired glucose tolerance (IGT) related peripheral neuropathy. *J*  
496 *Neurol Sci* 270: 165–171, 2008.  
497
- 498 21. **Grieve, D.W., Cavanagh, P.R., Pheasant, S.** Prediction of gastrocnemius length  
499 from knee and ankle joint posture. In: Asmussen, E., Jorgensen, K. (Eds.),  
500 *Biomechanics*, vol. VI-A. University Park Press, Baltimore, MD, pp. 405–412,  
501 1978.  
502

- 503 22. **Handsaker JC, Brown SJ, Bowling FL, Marple-Horvat DE, Boulton AJM,**  
504 **Reeves ND.** People with diabetic peripheral neuropathy display a decreased  
505 stepping accuracy during walking: potential implications for risk of tripping. *Diabet*  
506 *Med* 33: 644-649, 2016.
- 507
- 508 23. **Ishikawa M, Komi PV, Grey MJ, Lepola V, Bruggemann GP.** Muscle-tendon  
509 interaction and elastic energy usage in human walking. *J Appl Physiol* 99: 603–  
510 608, 2005.
- 511
- 512 24. **Ker RF, Bennett MB, Bibby SR, Kester RC, Alexander RM.** The spring in the  
513 arch of the human foot. *Nature* 325: 147–149, 1987.
- 514
- 515 25. **Lichtwark G, Wilson M.** In vivo mechanical properties of the human Achilles  
516 tendon during one-legged hopping. *J Exp Biol* 208: 4715–4725, 2005.
- 517
- 518 26. **Maganaris CN, Baltzopoulos V, Sargeant AJ.** Changes in Achilles tendon  
519 moment arm from rest to maximum isometric plantarflexion. *J Physiology* 510:  
520 977–985, 1998.
- 521
- 522 27. **Maganaris CN, Narici MV, Maffulli N.** Biomechanics of the Achilles tendon.  
523 *Disability and Rehabilitation* 30: 1542–1547, 2008.
- 524
- 525 28. **Maganaris CN, Paul JP.** In vivo human tendon mechanical properties. *J Physiol*  
526 521: 307–313, 1999.
- 527
- 528 29. **Martinelli AR, Mantovani AM, Nozabieli AJL, Ferreira DMA, Barela JA,**  
529 **Camargo MR De, Fregonesi CEPT.** Muscle strength and ankle mobility for the  
530 gait parameters in diabetic neuropathies. *Foot* 23: 17–21, 2013.
- 531
- 532 30. **Menz HB, Lord SR, St George R, Pod B, Fitzpatrick RC.** Walking stability and  
533 sensorimotor function in older people with diabetic peripheral neuropathy. *Arch*  
534 *Phys Med Rehabil* 85: 245–252, 2004.
- 535
- 536 31. **Peltonen J, Cronin NJ, Stenroth L, Finni T, Avela J.** Viscoelastic properties of  
537 the Achilles tendon in vivo. *SpringerPlus* 2: 1-8, 2013.
- 538
- 539 32. **Petrovic M, Deschamps K, Verschueren SM, Bowling FL, Maganaris CN,**  
540 **Boulton AJM, Reeves ND.** Is the metabolic cost of walking higher in people with  
541 diabetes? *J Appl Physiol* 120: 55-62, 2016.
- 542
- 543 33. **Reddy GK.** Cross-linking in collagen by nonenzymatic glycation increases the  
544 matrix stiffness in rabbit Achilles tendon. *Exp Diabetes Res* 5: 143–153, 2004.
- 545
- 546 34. **Reddy GK.** Glucose-mediated in vitro glycation modulates biomechanical  
547 integrity of the soft tissues but not hard tissues. *J Orthop Res* 21: 738–743, 2006.
- 548

- 549 35. **Reddy GK, Stehno-Bittel L, Enwemeka CS.** Glycation-induced matrix stability  
550 in the rabbit Achilles tendon. *Arch Biochem Biophys* 399: 174–180, 2002.  
551
- 552 36. **Reeves ND.** Adaptation of the tendon to mechanical usage. *J Musculoskelet*  
553 *Neuronal Interact* 6: 174–180, 2006.  
554
- 555 37. **Reeves ND, Narici MV, Maganaris CN.** Strength training alters the viscoelastic  
556 properties of tendons in elderly humans. *Muscle Nerve* 28: 74–81, 2003.  
557
- 558 38. **Roberts TJ.** The integrated function of muscles and tendons during locomotion.  
559 *Comp Biochem Physiol A Mol Integr Physiol* 133: 1087–1099, 2002.  
560
- 561 39. **Roberts TJ, Konow N.** How tendons buffer energy dissipation by muscle. *Exerc*  
562 *Sport Sci Rev* 41: 186–193, 2013.  
563
- 564 40. **Rugg SG, Gregor RJ, Mandelbaum BR, Chiu L.** In vivo moment arm  
565 calculations at the ankle using magnetic resonance imaging (MRI). *Journal of*  
566 *Biomechanics* 23, 495–501, 1990.  
567
- 568 41. **Spanjaard M, Reeves ND, Dieen JV, Baltzopoulos V, Maganaris CN.**  
569 Gastrocnemius muscle fascicle behavior during stair negotiation in humans. *J*  
570 *Appl Physiol* 102: 1618–1623, 2007.  
571
- 572 42. **Spanjaard M, Reeves ND, Dieen JV, Baltzopoulos V, Maganaris CN.** Lower-  
573 limb biomechanics during stair descent: influence of step-height and body mass.  
574 *J Exp Biol* 211: 1368–1375, 2008.  
575
- 576 43. **Van Den Bogert AJ, Smith GD, Nigg BM.** In vivo determination of the  
577 anatomical axes of the ankle joint complex: an optimization approach. *J Biomech*  
578 27: 1477-1488, 1994.  
579
- 580 44. **Van Dieren S, Beulens JW, Van der Schouw YT, Grobbee DE, Neal B.** The  
581 global burden of diabetes and its complications: an emerging pandemic. *Eur J*  
582 *Cardiovasc Prev Rehabil* 17: 3-8, 2010.  
583



585 Figure 1. A linear 7.5 MHz probe (A) with 60 mm field of view used for scanning the  
 586 gastrocnemius muscle. A custom-built fixation device made of Velcro straps and a  
 587 plastic cast moulded to fit the general contour of the calf (B) was used to secure the  
 588 probe around the left lower leg, in the mid-sagittal plane of the gastrocnemius muscle  
 589 with extra strapping added to further minimise any probe movement (C).  
 590



591  
 592 Figure 2. Typical sonograph of the GM muscle. The fascicular trajectory between the  
 593 two aponeurosis, as well as the pennation angle ( $\alpha$ ) are highlighted in white. SA,  
 594 superficial aponeurosis; MG, gastrocnemius medialis muscle; DA, deep aponeurosis.  
 595

596  
 597  
 598  
 599  
 600  
 601

602 *Table 1. Participant characteristics and results from neuropathy assessments.*

Variable	Group		
	Ctrl	DM	DPN
Age (yr)	55 (7)	57 (8)	61 (7)
BMI (kg/m <sup>2</sup> )	26 (4)	28 (4)	29 (5)
mNDS (Score/10)	1 (1)	2 (1)	7 (2)**
VPT (Volts)	6.1 (3)	8.2 (4)	27.4 (9)**
Diabetes duration (years)	-	14 (13)	17 (11)
Type 1 diabetes	-	6	4
Type 2 diabetes	-	14	9

603  
 23



604 Healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) and  
605 diabetic patients with moderate/severe neuropathy (DPN, n=13). Significant differences  
606 from the Ctrl group are denoted by \*\* ( $P < 0.01$ ). BMI = body mass index, mNDS =  
607 modified neuropathy disability score, VPT = vibration perception threshold. Values are  
608 means (standard deviations).  
609

610 Table 2. *Achilles and plantarflexor muscle-tendon parameters during walking.*

	<b>Ctrl</b>		<b>DM</b>		<b>DPN</b>	
	Self-selected	<b>1 m/s</b>	Self-selected	<b>1 m/s</b>	Self-selected	<b>1 m/s</b>
Walking speed (m/s)	1.43 (0.29)	1.03 (0.17)	1.33 (0.36)	1.04 (0.21)	1.30 (0.34)	0.98 (0.20)
Stiffness (N/mm)	210 (41)	186 (34)	231 (46)**	194 (39)**	240 (49)**	202 (37)**




611

Hysteresis (%)	18 (3)	17 (3)	21 (5)**	19 (4)*	24 (6)**	21 (5)**
Standing fascicle length (cm)	5.15 (1.5)		5.08 (1.4)		5.19 (1.3)	
Tendon length change (cm)	1.81 (1.0)	1.67 (0.7)	1.66 (0.5)*	1.51 (0.6)*	1.54 (0.8)**	1.47 (0.6)**
Fascicle length change (cm) 10-70 % of stance (loading)	0.58 (0.08)	0.53 (0.19)	0.42 (0.05)**	0.39 (0.06)**	0.38 (0.12)**	0.44 (0.14)**
Fascicle length change (cm) 70-100% of stance (unloading)	0.54 (0.04)	0.50 (0.12)	0.38 (0.04)**	0.33 (0.04)**	0.31 (0.07)**	0.37 (0.11)**
MTC length change (cm) 10-70 % of stance (loading)	1.21 (0.2)	1.11 (0.3)	0.89 (0.3)**	0.81 (0.2)*	0.76 (0.2)**	0.69 (0.1)**
MTC length change (cm) 70-100% of stance (unloading)	1.44 (0.1)	1.20 (0.1)	0.97 (0.1)**	0.84 (0.1)**	0.63 (0.1)**	0.58 (0.1)**
Tendon length change (cm) 10-70 % of stance	1.96 (0.6)	1.71 (0.4)	1.65 (0.3)**	1.26 (0.4)**	1.18 (0.5)**	0.81 (0.4)**
Tendon length change (cm) 70-100% of stance	1.92 (0.4)	1.82 (0.3)	1.63 (0.2)**	1.41 (0.2)**	0.78 (0.3)**	1.15 (0.2)**
Achilles Tendon forces (N)	2666 (242)	2343 (288)	2609 (167)*	2256 (290)**	2150 (177)**	2288 (241)**
Ankle RoM (deg)	26.4 (7.9)	25.1 (8.7)	25.3 (7.1)**	24.2 (8.1)**	25.1 (8.6)**	22.3 (9.5)**
Knee RoM (deg)	69.7 (26.1)	67.8 (24.9)	67.0 (21.5)**	66.0 (21.3)**	64.8 (30.2)**	64.7 (23.5)**
Pennation angle change (deg) 10-70% stance (loading)	26.8 (6.3)	24.9 (3.4)	25.7 (8.9)**	24.7 (5.0)**	25.1 (9.2)*	22.4 (8.0)*
Pennation angle change (deg) 70-100% stance (unloading)	31.9 (9.9)	30.7 (7.2)	29.6 (6.1)**	29.2 (6.9)**	28.8 (8.9)*	22.8 (7.7)**

612 Achilles and plantarflexor muscle-tendon parameters during walking for healthy controls (Ctrl; n=23), diabetic  
613 patients with no neuropathy (DM; n=20) and diabetic patients with moderate/severe neuropathy (DPN; n=13).  
614 Values are group means and SD; Significant differences from the Ctrl group are denoted by \*(P<0.05) or  
615 \*\*(P<0.01). MTC – muscle-tendon complex; RoM – range of motion.

616




### 617 Self-selected walking speed



618

619 **1.0 m/s**

620




621

622 Figure 3. Muscle fascicle length, MTC length and tendon length changes, respectively while walking at self-selected speed  
 623 and 1.0 m/s. Values are means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13).


624

625 **Self-selected walking speed**



626

627 **1.0 m/s**




628

629 Figure 4. From left to right: ankle and knee range of motion (RoM) and ankle joint moment (AJM) during stance phase while  
630 walking at self-selected walking speed and 1.0 m/s for healthy controls (Ctrl), diabetic patients with no neuropathy (DM),  
631 and diabetic patients with moderate/severe neuropathy (DPN). Values are means. Line graphs: Ctrl - solid line (n=23), DM -  
632 dotted line (n=20), DPN - dashed line (n=13).


633

634

635



636  
 637 Figure 5. Achilles tendon force-elongation curves while walking at self-selected speed  
 638 (4a) and at 1 m/s (4b) for healthy controls (Ctrl), diabetic patients with no neuropathy  
 639 (DM), and diabetic patients with moderate/severe neuropathy (DPN). Values are  
 640 means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line  
 641 (n=13).  
 642



643  
 644 Figure 6. Isometric plantarflexion maximal voluntary contraction (MVC) strength for  
 645 healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) and  
 646 diabetic patients with moderate/severe neuropathy (DPN, n=13). Values are means and  
 647 SD. Significant differences from the Ctrl group are denoted by \*\* (P<0.01).